Analysis of influential factors for dose-corrected trough concentration of amisulpride based on therapeutic drug monitoring
- VernacularTitle:基于治疗药物监测的氨磺必利剂量校正浓度影响因素分析
- Author:
Yiqi WANG
1
,
2
;
Luyao CHANG
1
,
2
;
Ran FU
1
,
2
;
Lingjiao WANG
1
,
2
;
Jing YU
1
,
2
;
Chunhua ZHOU
1
Author Information
1. Dept. of Clinical Pharmacy，the First Hospital of Hebei Medical University，Shijiazhuang 050000，China
2. The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province，Shijiazhuang 050000，China
- Publication Type:Journal Article
- Keywords:
amisulpride;
therapeutic drug monitoring
- From:
China Pharmacy
2022;33(24):3020-3024
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the influential factors for dose-corrected trough concentration （C/D） of amisulpride， and to provide reference for rational use of it in clinic. METHODS The results of the last serum concentration monitoring and relevant medical data of schizophrenic inpatients who were monitored for the treatment of amisulpride in the Mental Health Center of the First Hospital of Hebei Medical University from March to November 2021 were collected retrospectively and analyzed the effects of age， sex， body mass index （BMI）， serum creatinine level， and combined medication on the C/D value of amisulpride. RESULTS A total of 133 schizophrenic inpatients were included， and median dose of amisulpride was 600.00 mg/d， median serum concentration was 332.57 ng/mL， and median value of C/D was 0.61 ng·d/（mL·mg）. The serum concentration of 49 patients was within the recommended range of relevant guideline （100-320 ng/mL）， and 27 patients exceeded the laboratory warning concentration （640 ng/mL）. There was no statistical significance in drug dose， serum concentration or C/D value among the patients of different genders （P＞0.05）. The serum concentration of minor patients was significantly lower than that of adult patients （P＜0.05）， but there was no statistical significance in drug dose or C/D value between minor patients and adult patients （P＞0.05）. The C/D value of amisulpride in obese patients （BMI＞28 kg/m2） was significantly lower than that in normal patients （BMI 18.5- 23.9 kg/m2）； the combination of olanzapine， sodium valproate and benzodiazepines did not affect the C/D value of amisulpride （P＞0.05）； the level of serum creatinine in patients was not related to the dose of amisulpride （r＝0.081， P＞0.05）， but was positively related to the C/D value of the drug （r＝0.285， P＜0.05）. CONCLUSIONS The age， BMI and serum creatinine level of patients are closely related to the C/D value of amisulpride. In the clinical treatment of schizophrenia with amisulpride， we should fully consider the patient’s age， body mass， serum creatinine and other factors， and develop a personalized drug regimen for patients to ensure the safety and effectiveness of treatment.
